Schering Corporation

Merck Sharp + Dohme Corp.

Dynavax Technologies Corporation

Trisalus Life Sciences, Inc.

Surefire Medical, Inc.

Robert A Kastelein

J Fernando Bazan

Kevin W Moore

Rene De Waal Malefyt

Christi L Parham

Madaline Chirica

Jacqueline C Timans

Marie-Ange Buyse

Carlo Boutton

Bruno Dombrecht

Donna M Rennick

Maribel Beaumont

Daniel M Gorman

Yong-Jun Liu

David Vlerick

Gerard Zurawski

Terrill K McClanahan

Edward P Bowman

Erin E Murphy

Stefan Karl-Heinz Pflanz

Jeanne Cheung

Juha Punnonen

Satwant K Narula

Jason R Chan

Robert L Coffman

Cristiana Guiducci

Daniel J Cua

Gerard T Hardiman

Theodore R Sana

Andrew Evan Denker

Michael Rosenzweig

Martin Oft

Joseph A Hedrick

Luigina Romani

Scott W Altmann

Melanie A Kleinschek

Birgit Oppmann

Pedro A Reche-Gallardo

Alissa A Chackerian

Sergio A Lira

Bjorn Victor

David Ross Kaufman

Maria T Wiekowski

Fernando L Rock

Robert S Janssen

Vassili Soumelis

Uyen Truong Phan

Lynette M Dowling

Edward Bowman

Svetlana Sadekova

Johannes Eduard Maria Antonius Debets

Vassilli Soumelis

Stephen W K Ho

Ying Yu

Rachel R Caspi

Manfred Kopf

Van T Tsai

Fernando J Bazan

Katia Boniface

Elaine M Pinheiro

Deborah A Law

Phyllis Silver

Kristian Sass Bak-Jensen

Jochen Schmitz

Kathy Lynn Miller

Edward Paul Bowman

Brent S Mckenzie

The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

PD1 and/or LAG3 binders

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.

Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer

The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

CTLA4 binders

The present invention relates to methods of treating a cell proliferation disorder (e.g., cancer) comprising administering: (a) a compound having the Formula (I), wherein Ror Rare as herein defined, or a pharmaceutically acceptable salt thereof; and (b) an anti-human PD-1 antibody or antigen binding fragment thereof to a human patient in need thereof. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers. 

Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist

Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer

The present invention provides multispecific molecules, e.g., comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

PD1/CTLA4 binders

Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.

Methods of modulating cytokine activity; related reagents

Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Antagonists of IL-23P19 for treatement of atopic dermatitis

Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.

Binding compounds for IL-27

Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.

Use of IL-23 antagonists for treatment of infection

Growing community of inventors

Portola Valley, CA, United States of America

Robert A Kastelein